While composite tissue-based biomarkers have been explored by investigators in the HER2-positive setting, such as in the above studies, the incorporation of imaging and tissue-based biomarkers in the assessment of response to HER2-directed therapy without chemotherapy in early breast cancer is relatively unique. Here, ERBB2 is linked to breast carcinoma.